Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBITDA (2021 - 2025)

Historic EBITDA for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to -$3.6 million.

  • Immunocore Holdings' EBITDA fell 12978.39% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year decrease of 2306.14%. This contributed to the annual value of -$48.6 million for FY2024, which is 3176.68% down from last year.
  • As of Q3 2025, Immunocore Holdings' EBITDA stood at -$3.6 million, which was down 12978.39% from -$3.8 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year EBITDA high stood at $12.0 million for Q3 2024, and its period low was -$51.1 million during Q4 2021.
  • Its 5-year average for EBITDA is -$16.6 million, with a median of -$11.3 million in 2023.
  • Examining YoY changes over the last 5 years, Immunocore Holdings' EBITDA showed a top increase of 18531.86% in 2024 and a maximum decrease of 450856.64% in 2024.
  • Immunocore Holdings' EBITDA (Quarter) stood at -$51.1 million in 2021, then surged by 36.43% to -$32.5 million in 2022, then skyrocketed by 98.24% to -$572000.0 in 2023, then tumbled by 4508.57% to -$26.4 million in 2024, then soared by 86.46% to -$3.6 million in 2025.
  • Its EBITDA was -$3.6 million in Q3 2025, compared to -$3.8 million in Q2 2025 and $5.7 million in Q1 2025.